Description de l'entreprise
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets five hematology/oncology drugs, and expects an FDA decision on another hematology drug later this year. Additionally, Spectrum's pipeline includes three drugs targeting blockbuster markets in advanced stages of clinical development. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.
Conseil d'administration & Conseil de surveillance
| PDG |
| Joseph Turgeon |
| Conseil d'administration |
| Kurt Gustafson, Francois Lebel, Keith M. McGahan, Thomas J. Riga |
| Conseil de surveillance |
| William L. Ashton, Bernice R. Welles, Dolatrai M. Vyas, Jeffrey L. Vacirca, Joseph W. Turgeon, Nora Brennan, Seth H.Z. Fischer |
Données de l'entreprise
| Nom: |
Spectrum Pharmaceuticals Inc. |
| Adresse: |
11500 S. Eastern Avenue, Suite 240,Henderson, NV 89052, USA |
| Téléphone: |
+1-702-935-6300 |
| Fax: |
+1-702-260-7405 |
| Courriel: |
-
|
| Internet: |
https://www.sppirx.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
61.22% |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
Shiv Kapoor |
| Téléphone IR: |
- |
| IR-Fax: |
- |
| E-mail IR: |
IR@sppirx.com
|
